← Back to Search

Laser Therapy

selective laser trabeculoplasty for Glaucoma (SLTRepeat Trial)

Phase 3
Waitlist Available
Led By William G Hodge, MD, PhD
Research Sponsored by Lawson Health Research Institute
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
two sighted eyes
Over age of 18 yo.
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 36 months after initial enrollment of the primary study
Awards & highlights

SLTRepeat Trial Summary

Lasers are important therapy in glaucoma. They are a pivotal point in treatment between medical and surgical care. Over the last 10 years a new laser has emerged as the usual laser treatment: Selective laser trabeculoplasty (SLT). SLT works as well as the older laser used: argon laser trabeculoplasty (ALT). However SLT has many theoretical benefits over ALT including causing less damage to the tissue it affects. One of the potential patient centered benefits of this laser is that it may be repeatable. It is even possible that the old laser ALT may be useable after an SLT treatment. This study aims to uncover whether repeat laser is possible after SLT and if so which laser is more effective (ALT vs SLT). The potential of repeating laser therapies may delay surgical treatment and its complications. Also understanding which laser to use will help eye doctors know how to treat their patients at this point of the disease.

SLTRepeat Trial Eligibility Criteria

Inclusion Criteria

You may be eligible if you check “Yes” for the criteria below

SLTRepeat Trial Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~36 months after initial enrollment of the primary study
This trial's timeline: 3 weeks for screening, Varies for treatment, and 36 months after initial enrollment of the primary study for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Intraocular Pressure
Secondary outcome measures
SLT repeatability of long term follow up in glaucoma patients
To compare any adverse events between the two groups at all visits.
To compare the IOP lowering effect between the groups at other postoperative visits
+2 more

SLTRepeat Trial Design

2Treatment groups
Active Control
Group I: selective laser trabeculoplastyActive Control2 Interventions
Post 2005, a newer mode of laser therapy, selective laser trabeculoplasty (SLT) has emerged as the standard of care laser. There are many potential advantages to SLT but to date these advantages are only theoretical. The most important potential clinical advantage of SLT is that it causes less damage to the tissue it targets.
Group II: Argon laser trabeculoplastyActive Control2 Interventions
Up to the year 2005, the vast majority of ophthalmologists used Argon laser trabeculoplasty (ALT) as the mode of laser therapy. ALT is effective but its most significant problem is that its effectiveness decreases with re-treatment since the tissue it targets (the trabecular meshwork) is changed by the laser rendering repeat treatments less effective.

Find a Location

Who is running the clinical trial?

Lawson Health Research InstituteLead Sponsor
655 Previous Clinical Trials
413,200 Total Patients Enrolled
5 Trials studying Glaucoma
368 Patients Enrolled for Glaucoma
William G Hodge, MD, PhDPrincipal InvestigatorLawson Research Institute, Univ. of Western Ontario

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.
~11 spots leftby Mar 2025